Suven Pharmaceuticals on Thursday said it will merge with contract development and manufacturing organisation platform Cohance Lifesciences.
The entities announced a proposed scheme of amalgamation for the purpose.
Upon the scheme becoming effective, all shareholders of Cohance will be issued 11 shares of Suven for every 295 shares held in the former, Suven Pharmaceuticals said in a statement.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The new shares of Suven will be traded on the NSE and BSE, it added.
The transaction is expected to conclude over the next 12-15 months, subject to receipt of all relevant shareholder and regulatory approvals.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
"This is a transformative step in Suven's journey of growth and building a respected integrated CDMO player," Suven Executive Chairman Annaswamy Vaidheesh said.
In December 2022, Suven Pharmaceuticals promoter Jasti family offloaded a 50.1 per cent stake in the company to global private equity investor Advent International.
In 2022, Advent launched Cohance Lifesciences, a new brand identity for its API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing company) platform.
Now, Advent entities will hold 66.7% and the public shareholders will own 33.3% of the combined entity, the entities said.
The platform comprises Advent's three portfolio companies - RA Chem Pharma, ZCL Chemicals and Avra Laboratories.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
